Adjuvant therapy of pancreatic cancer

Cancer Journal

Volumn 13, Issue 3, 2007, Pages 185-191

  Willett, Christopher G ^a   Czito, Brian G ^a   Bendell, Johanna C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; PACLITAXEL; PLACEBO;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; DUODENUM ULCER; GASTROINTESTINAL HEMORRHAGE; HUMAN; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; STOMACH ULCER; THROMBOCYTOPENIA; TREATMENT FAILURE; UNITED STATES; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOLOGICAL THERAPY; METHODOLOGY; PANCREAS TUMOR; PANCREATICODUODENECTOMY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

BIOLOGICAL THERAPY; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 38549148050     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318074e071     Document Type: Review

References (63)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg. 165:68-72; discussion 72-3, 1993.
3. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg. 2003;237:74-85.
4. Evans D, Abbruzzese J, Willett C. Cancer of the Pancreas. 6th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001.
5. Moosa AR. Surgical treatment of pancreatic cancer. Am J Surg. 1986; 152:503.
6. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med. 1992;326:455-465.
7. Whipple AO, Parson WV, Mullin CR. Treatment of carcinoma of the ampulla of Vater. Ann Surg. 1935;102:763.
8. Warren KW, Braasch JW, Thum CW. Carcinoma of the pancreas. Surg Clin North Am. 1968;48:601-618.
9. Howard JM. Pancreato-duodenectomy: forty-one consecutive Whipple resections without an operative modality. Ann Surg. 1968;168:629-640.
10. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671-1677.
11. Sohn TA, Lillemoe KD, Cameron JL, et al. Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome. Ann Surg. 1999;229:393-400.
12. Kozuschek W, Reith HB, Waleczek H, et al. A comparison of long term results of the standard Whipple procedure and the pylorus preserving pancreatoduodenectomy. J Am Coll Surg. 1994;178:443-453.
13. Takao S, Aikou T, Shinchi H, et al. Comparison of relapse and long-term survival between pylorus-preserving and Whipple pancreaticoduodenectomy in periampullary cancer. Am J Surg. 1998;176:467-470.
14. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg. 1995;221: 721-731; discussion 731-733.
15. Magistrelli P, Masetti R, Coppola R, et al. Pancreatic resection for periampullary cancer in elderly patients. Hepatogastroenterology. 1998; 45:242-247.
16. Sohn TA, Yeo CJ, Cameron JL, et al. Should pancreaticoduodenectomy be performed in octogenarians? J Gastrointest Surg. 1998;2:207-216.
17. Lillemoe KD. Current management of pancreatic carcinoma. Ann Surg. 1995;221:133-148.
18. Yeo CJ, Cameron JL, Sohn TA, et al. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: comparison of morbidity and mortality and short-term outcome. Ann Surg. 2002;236:355-366.
19. Robinson EK, Lee JE, Lowy AM, et al. Reoperative pancreaticoduode-nectomy for periampullary carcinoma. Am J Surg. 1996;172:432-437; discussion 437-438.
20. Sosa JA, Bowman HM, Gordon TA, et al. Importance of hospital volume in the overall management of pancreatic cancer. Ann Surg. 1998;228:429-438.
21. Tepper J, Nardi G, Suitt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer. 1976;37:1519-1524.
22. Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66:56-61.
23. Whittington R, Bryer MP, Haller DG, et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 1991; 21:1137-1143.
24. Ozaki H. Improvement of pancreatic cancer treatment from the Japanese experience in the 1980s. Int J Pancreatol. 1992;12:5-9.
25. Westerdahl J, Andren-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer - local or hepatic? Hepatogastroenterology. 1993;40: 384-387.
26. Willett CG, Lewandrowski K, Warshaw AL, et al. Resection margins in carcinoma of the head of the pancreas: implications for radiation therapy. Ann Surg. 1993;217:144-148.
27. Allema JH, Reinders ME, van Gulik TM, et al. Prognostic factors for survival after pancreaticoduodenectomy for patients with carcinoma of the pancreatic head region. Cancer. 1995;75:2069-2076.
28. Kalser MH, Ellenberg SS. Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120:899-903.
29. Further evidence of effective adjuvant combined radiation and chemo- therapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer. 1987;59:2006-2010.
30. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776-782; discussion 782-784.
31. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradio-therapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001;358:1576-1585.
32. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
33. Neuhaus P, Oettle H, Post S, et al. A randomised, prospective, multi-center, phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer. J Clin Oncol. 2005;23(16 suppl):8197.
34. Regine WF, Winter KW, R. A., et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adencarcinoma. J Clin Oncol. 2006;24(18 suppl): 4007.
35. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg. 1997;225:621-633; discussion 633-636.
36. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567-579.
37. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant che-moradiation therapy after pancreaticoduodenectomy for pancreatic ade-nocarcinoma. Am J Surg. 2003;185:476-480.
38. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 1991; 161:120-124; discussion 124-125.
39. Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenec-tomy for adenocarcinoma of the pancreas. J Clin Oncol. 1997;15:928-937.
40. Evans DB, Pisters PW, Lee JE, et al. Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas. J Hepatobiliary Pancreat Surg. 1998;5:242-50.
41. Wayne JD, Abdalla EK, Wolff RA, et al. Localized adenocarcinoma of the pancreas: the rationale for preoperative chemoradiation. Oncologist. 2002;7:34-45.
42. Raut CP, Evans DB, Crane CH, et al. Neoadjuvant therapy for resectable pancreatic cancer. Surg Oncol Clin N Am. 2004;13:639-661, ix.
43. White RR, Tyler DS: Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am. 2004;13:675-684. ix-x.
44. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. 1992;127:1335-1339.
45. Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation pre-operative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol. 1998;16:3843-3850.
46. Muler JH, McGinn CJ, Normolle D, et al. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol. 2004;22:238-243.
47. Wolff RA, Crane CH, Xiong HQ, et al. Preliminary analysis of preoperative systemic gemcitabine (GEM) and cisplatin (CIS) followed by GEM-based chemoradiation for resectable pancreatic adenocarcinoma. Paper presented at: 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA.
48. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 2002;20:2537-2544.
49. Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 1999;17:2208-2212.
50. Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer. 2003;34:107-116.
51. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19:4202-4208.
52. McGinn CJ, Talamonti MS, Small W, et al. A phase II trial of full-dose gemcitabine with concurrent radiation therapy in patients with resectable or unresectable non-metastatic pancreatic cancer. Paper presented at: 2004 Gastrointestinal Cancers Symposium; January 22-24, 2004; San Francisco, CA.
53. Talamonti MS, Catalano PJ, Vaughn DJ, et al. Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol. 2000;18:3384-3389.
54. Safran H, Akerman P, Cioffi W, et al. Paclitaxel and concurrent radiation therapy for locally advanced adenocarcinomas of the pancreas, stomach, and gastroesophageal junction. Semin Radiat Oncol. 1999;9:53-57.
55. Rich T, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol. 2004;27:51-56.
56. Moore M, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Paper presented at: 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL.
57. Kortmansky J, O'Reilly E, Minsky B, et al. A phase I trial of erlotinib, gemcitabine, and radiation for patients with locally-advanced, unresectable pancreatic cancer. Paper presented at: 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL.
58. Iannitti D, Dipetrillo T, Barnett J, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Paper presented at: 2005 Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, FL.
59. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004;22:2610-2616.
60. Krempien RC, Munter MW, Timke C, et al. Phase II study evaluating trimodal therapy with cetuximab intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer (ISRCTN56652283). J Clin Oncol. 2006;24(18 suppl):4100.
61. Pipas JM, Zaki B, Suriawinata AA, et al. Cetuximab, intensity-modulated radiotherapy (IMRT), and twice-weekly gemcitbaine for pancreatic adenocarcinoma. J Clin Oncol. 2006;24(18 suppl):14056.
62. Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006;24:1145-1151.
63. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040.